Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
Abstract Background Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. Standard therapy for heart failure (HF) is recommended for CTRCD, but th...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | Cardio-Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40959-020-00078-4 |